Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 9, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Network meta-analysis of first-line R-CHOP-based regimens in MYC/BCL2 double-expressor diffuse large B-cell lymphoma.

Hao Cheng1, Lin Zeng1,2, Xuanzhang Li1

  • 1Department of Hematology/Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.

Frontiers in Immunology
|July 8, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human CD24<sup>+</sup> dental papilla cells are competent seed cells for dentin-pulp regeneration via BMP2/SIRT1 axis.

Nature communications·2026
Same author

Propensity-matched study of liposomal doxorubicin vs. doxorubicin in first-line DLBCL treatment: efficacy and safety.

Frontiers in medicine·2026
Same author

Resolving tooth development at single-cell resolution: advancing dental regeneration.

Frontiers in cell and developmental biology·2026
Same author

Identification of GLDN<sup>+</sup> odontogenic stem cells as crucial for human tooth development and regeneration.

International journal of oral science·2026
Same author

Five-Year Slaughterhouse-Based Surveillance of <i>Echinococcus granulosus</i> in Sheep from Yili, Northwest Xinjiang, China.

Pathogens (Basel, Switzerland)·2026
Same author

Analysis of Echinococcus multilocularis complete mitogenomes: evidence for the historical spread from Central Asia to the Northern Hemisphere.

International journal for parasitology·2026

Pola-R-CHP demonstrated improved progression-free survival in double-expressor lymphoma (DEL) patients compared to standard R-CHOP. While no regimen significantly improved overall survival, Pola-R-CHP showed a favorable benefit-risk profile, warranting further investigation in DEL-specific trials.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Double-expressor lymphoma (DEL) is a subtype of diffuse large B-cell lymphoma (DLBCL) characterized by MYC and BCL2 overexpression without gene rearrangements.
  • DEL patients typically exhibit poorer outcomes with standard R-CHOP treatment.
  • Existing research lacks direct head-to-head comparisons of novel R-CHOP-based regimens specifically for DEL.

Purpose of the Study:

  • To compare the efficacy and safety of four modified R-CHOP regimens against standard R-CHOP in treatment-naïve DEL patients.
  • To identify the optimal R-CHOP-based regimen for improving progression-free survival (PFS) and overall survival (OS) in DEL.
  • To assess the benefit-risk profile of novel regimens in the context of DEL treatment.

Main Methods:

Keywords:
MYC/BCL2R-CHOPdiffuse large B-cell lymphomadouble-expressor lymphomanetwork meta-analysispolatuzumab vedotintucidinostat

Related Experiment Videos

Last Updated: Jul 9, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

  • A frequentist network meta-analysis was conducted, searching PubMed, EMBASE, Cochrane Library, and Web of Science through December 2025.
  • Four studies (CAVALLI, DEB, POLARIX, REMoDL-B) involving 1,016 DEL patients were included, comparing Pola-R-CHP, Ven-R-CHOP, VR-CHOP, and CR-CHOP against R-CHOP.
  • Efficacy (PFS, OS) and safety (adverse events) were analyzed using indirect comparisons within a star-shaped network, supplemented by Bayesian analysis and sensitivity analyses.

    • Main Results:

    • Pola-R-CHP was the only regimen significantly improving PFS (HR=0.65, 95% CI=0.45-0.94), reducing progression risk by 35%.
    • No regimen demonstrated a significant improvement in OS, though CR-CHOP showed a favorable trend (HR=0.77, 95% CI=0.53-1.13).
    • Ven-R-CHOP was associated with significantly increased grade 3-4 thrombocytopenia, neutropenia, and anemia, while Pola-R-CHP had a comparable safety profile to R-CHOP.

    Conclusions:

    • Pola-R-CHP may offer a favorable benefit-risk profile for treating double-expressor lymphoma (DEL) patients, primarily due to improved PFS.
    • Current evidence is based on indirect subgroup analyses with moderate-to-low certainty, necessitating caution.
    • Prospective, DEL-specific clinical trials are essential to confirm the efficacy and safety of Pola-R-CHP and other novel regimens in this patient population.